Two Stocks you Can Bet on Frontier Communications (NASDAQ:FTR), Juniper Networks (NYSE:JNPR)

Frontier Communications Corporation (NASDAQ:FTR) kept active in under and overvalue discussion, FTR holds price to book ratio of 0.86 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation.

Frontier Communications Corporation (FTR) released recently that its Executive Vice President and Chief Financial Officer, Perley McBride, is planned to present at the UBS 44th Annual Global Media and Communications Conference in New York, N.Y. on Monday, December 5, 2016, at 10:45 A.M. Eastern Time. A live webcast will be accessible at Frontier’s Investor Relations website under “Webcasts and Presentations.”

On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.  The firm has price volatility of 4.36% for a week and 3.39% for a month. Its beta stands at 0.66 times. Narrow down four to firm performance, its weekly performance was -3.81% and monthly performance was 13.14%.

Juniper Networks, Inc. (NYSE:JNPR) runs in leading trade, it knocking up remains unchanged to traded at $26.93. JNPR attains analyst recommendation of 2.70 on scale of 1-5 with week’s performance of 0.56%.

To find out the technical position of JNPR, it holds price to book ratio of 2.15 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 12.09, and price to earnings ratio calculated as 17.40. The price to earnings growth ration calculated as 1.31. JNPR is presenting price to cash flow of 4.44 and free cash flow concluded as 19.88.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 317.10%, and looking further price to next year’s EPS is 7.74%. While take a short look on price to sales ratio, that was 2.09 and price to earning ration of 17.40 attracting passive investors.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *